Article Dans Une Revue (Article De Synthèse) Clinica Chimica Acta Année : 2025

Human cystatin C in fibrotic diseases

Résumé

Human cystatin C (hCC), which has a pervasive distribution within body fluids and is ubiquitously expressed by numerous cells and tissues, is a highly potent extracellular inhibitor of cysteine proteases. Besides measurement of serum creatinine, which is the most widely used technique for appraising glomerular filtration rate (GFR), hCC has emerged as a relevant GFR biomarker, because its quantification in serum is less sensitive to interferences with factors such as age, muscle mass or diet. Moreover, there are growing body of evidence that hCC overexpression and/or oversecretion, which is primarily driven by TGF-β1, occur during fibrogenesis (cardiac, liver, oral, and lung fibrosis). Even though molecular mechanisms and signaling pathways governing the regulation of hCC remain to be deciphered more acutely, current data sustain that hCC expression relates to myofibrogenesis and that hCC could be a specific and valuable biomarker of fibrotic disease.
Fichier principal
Vignette du fichier
1-s2.0-S0009898124022691-main.pdf (3) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

hal-04876640 , version 1 (23-01-2025)

Licence

Identifiants

Citer

Gilles Lalmanach, Baptiste Rigoux, Alexis David, Mounia Tahri-Joutey, Fabien Lecaille, et al.. Human cystatin C in fibrotic diseases. Clinica Chimica Acta, 2025, 565, pp.120016. ⟨10.1016/j.cca.2024.120016⟩. ⟨hal-04876640⟩

Collections

UNIV-TOURS CEPR
0 Consultations
0 Téléchargements

Altmetric

Partager

More